Salute e Benessere

Pixium Vision announces receipt of € 1.8 million from the French Government as…

Pixium Vision announces receipt of € 1.8 million from the French Government as Research Tax Credit €1.8 million research tax credit received on June 7, 2023, to extend runway to the end of September 2023Lloyd Diamond participates at the Octane Ophthalmology Tech ForumEdison published an updated analyst report Paris, France, June 8 , 2023 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company...
Nasdaq GlobeNewswire
08/06/2023

Annual General Meeting 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June8 , 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3 rdfloor, 1228 Plan-les-Ouates, Switzerland.The agenda of the meeting will be as follows: ...
Nasdaq GlobeNewswire
08/06/2023

Press release Biocartis Group NV: Disclosure of transparency notification

PRESS RELEASEREGULATED INFORMATION8 June 2023, 7:00 CEST Disclosure of transparency notificationMechelen , Belgium,8June 2023– Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down...
Nasdaq GlobeNewswire
08/06/2023

Mendus AB: Mendus and NorthX Biologics to enter into strategic cell therapy…

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announces that it has entered into a manufacturing alliance with NorthX Biologics AB (“NorthX”). NorthX is a Contract Development and Manufacturing Organization (CDMO) and serves as the National Swedish Innovation Hub for the GMP manufacture of biologics used in vaccines, gene therapy and other advanced therapy medicinal products (ATMPs). Mendus and NorthX will...
Nasdaq GlobeNewswire
08/06/2023

Marketing Authorization Application for lecanemab as treatment for early…

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region and currently Eisai and BioArctic are preparing for a joint commercialization in the region. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen...
PR Newswire
08/06/2023

GENFIT Announces New Data at the European Association for the Study of the Liver…

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland);June7 , 2023-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present new data at the EASL Congress which will take place on June 21-24, 2023 in Vienna, Austria.Posters and Presentations GENFIT has had three abstracts accepted for poster...
Nasdaq GlobeNewswire
07/06/2023

Inventiva announces five scientific presentations at the EASL International…

Five poster presentations showing :the correlation between the improvement of hepatic steatosis and a robust increase in adiponectin levels, improvement in lipid profile and glycemic control in patients with non-cirrhotic NASH treated with lanifibranor.the Early improvement in ALT or AST being predictive of response pattern of liver histology as well as non-invasive hepatic and cardiometabolic biomarkers observed after 24-week treatment with lanifibranor in patients with non-cirrhotic...
Nasdaq GlobeNewswire
07/06/2023

BBS-Bioactive Bone Substitutes Plc: 57% of warrants 2-2022 (TO2) used for the…

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 7 June 2023 at 10.30 p.m. EESTBBS-Bioactive Bone Substitutes Plc: 57% of warrants 2-2022 (TO2) used for the subscription of shares, company raises EUR 162,000 in gross proceeds.The subscription period for BBS-Bioactive Bone Substitutes Plc's (“BBS” or “Company”) first series of warrants 2-2022 (TO2) ended on 2 June 2023. In total, 254 580 warrants 2-2022 (TO2) were used, corresponding to approximately 57.2 percent of the total...
Nasdaq GlobeNewswire
07/06/2023

FibroScan® now recommended in primary care settings, according to Landmark…

NICE found that the non-invasive technology from Echosens is a safe and effective way to improve patient outcomes and create a more efficient system for diagnosing liver disease in the early stages. This groundbreaking recommendation will allow FibroScan® patients to receive faster results in the diagnostic patient pathway and outside secondary care. As a result, this technology has the potential to revolutionize how healthcare providers diagnose and treat patients with liver conditions, such as…
PR Newswire
07/06/2023

Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line…

The central independent review concluded that the NIPU study did not meet the primary endpoint of progression-free survival (PFS). However, a statistically significant improvement in PFS for patients receiving UV1 was measured in a separate pre-defined local assessment at the participating hospitalsThe trial investigators also observed an improvement in overall survival in the UV1 arm over the control arm, although the data need to mature before a conclusion can be reachedSafety profile...
Nasdaq GlobeNewswire
07/06/2023

3D Printing Medical Devices Market worth $6.9 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=90799911 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=90799911 Browse in-depth TOC on "3D Printing Medical Devices Market" 135 - Tables 60 - Figures 280 - Pages 3D Printing Medical Devices Market Scope: Software and Services component segment to register a significant growth rate over the forecast period of 2023-2028 Based...
PR Newswire
07/06/2023

Fairtility Expands European Market Penetration with CHLOE EQ™, as Clinics in…

"Clinics across Europe have embraced CHLOE EQ™, and they are seeing the disruptive capabilities of the platform, both in terms of embryo selection and providing patients the most advanced and transparent IVF experience available," said Eran Eshed, CEO and Co-founder of Fairtility. "These clinics are charting the path forward as AI progresses to become part of the standard of care across the IVF journey." "Clinics acrossEuropehave embraced CHLOE EQ™, and they are seeing…
PR Newswire
07/06/2023

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of May 31 , 2023(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (June7 , 2023 - 6:00 pm)– As of May 31, 2023, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic...
Nasdaq GlobeNewswire
07/06/2023

Cholangiocarcinoma Clinical Trial Pipeline Analysis Demonstrates 65+ Key…

Key Takeaways from the Cholangiocarcinoma Pipeline Report Key Takeaways from the Cholangiocarcinoma Pipeline Report Request a sample and discover the recent advances in cholangiocarcinoma drug treatment @Cholangiocarcinoma Pipeline Report The cholangiocarcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage cholangiocarcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and...
PR Newswire
07/06/2023

Cambridge Healthcare Research Appoints the Head of their Competitive…

As Head of Solici, Walkden will lead a highly talented group of senior colleagues and their teams to deliver clients an unrivalled and market-beating understanding of their competitive landscape through CI [competitive intelligence]. As Head of Solici, Walkden will lead a highly talented group of senior colleagues and their teams to deliver clients an unrivalled and market-beating understanding of their competitive landscape through CI [competitive intelligence]. "I am delighted to be...
PR Newswire
07/06/2023

Generative Artificial Intelligence Tools Empowering Scientific Publications…

Turacoz unfurled the AI and medical writing (AIMW) brain trust initiative, an AI-focused community of like-minded individuals who like to understand and explore the opportunities provided by generative AI in medical writing. This initiative is aimed to gather insights, experiences, challenges faced in using AI and plausible solutions to improve the efficiency of different generative AI tools. The AIMW brain trust initiative has planned several small tangible and measurable practical activities…
PR Newswire
07/06/2023

Breaking Boundaries in Breast Cancer Screening: Densitas® and ScreenPoint…

"Pragmatic and scalable solutions for precision breast health are necessary to improve mammography quality and breast cancer diagnosis, both at the individual and population health levels," said Mo Abdolell, CEO of Densitas. "We are excited to partner with ScreenPoint in our shared vision to apply precision breast imaging to every mammogram taken at every screening exam to appropriately manage patients through their journey along breast cancer screening, diagnostic, treatment, and…
PR Newswire
07/06/2023

STREETDOCTORS APPOINTS NICK MAUGHAN AS PATRON

Nick Maughan, Founder of the Nick Maughan Foundation commented on the announcement: "I am honoured to have been asked to be the Patron of StreetDoctors. StreetDoctors is a remarkable charity which saves countless lives. Youth violence is one of the most pressing social issues in the U.K. today and StreetDoctors provides young people with the tools to act as first responders in emergencies, empowering them to keep themselves and others safe." Nick Maughan, Founder of the Nick Maughan...
PR Newswire
07/06/2023

BIOVAXYS REPORTS AGM RESULTS

James Passin (99.08% FOR) James Passin(99.08% FOR) Anthony Dutton(99.37% FOR) Craig Loverock(99.28% FOR) The following resolutions were also approved: Setting the number of Directors at three (99.41% in Favour) Re-appointing Dale Matheson Carr-Hilton LaBonte LLP, Chartered Professional Accountants as Auditor (99.60% in Favour) Re-approving the Company's Stock Option Plan (98.98% in Favour) A total of 28,747,103 common shares representing 19.44 % of the 147,841,627...
PR Newswire
07/06/2023

Nurse Next Door Announces England Master Franchise

Cathy Thorpe, President & CEO of Nurse Next Door, expressed her enthusiasm, stating, "We are incredibly excited to bring our unique concept of Happier Ageing™ to England with Prash and Karen. We firmly believe that seniors can age happily at home and our philosophy ensures care goes beyond just clinical tasks and allows for individuals to get back to doing the things they love." Cathy Thorpe, President & CEO of Nurse Next Door, expressed her enthusiasm, stating, "We are…
PR Newswire
07/06/2023

Nordic Nanovector - Notice of Annual General Meeting on 28 June 2023

For further information, please contact: For further information, please contact: IR enquiries Ludvik Sandnes, Interim CEO & CFO Cell: +47 907 43 017 Email: ir@nordicnanovector.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. Further information can be found at www.nordicnanovector.com. The following files are available for download: ...
PR Newswire
07/06/2023

Reporting of transactions made by persons discharging managerial…

Company announcement no. 29 - 237 June 2023 Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares In accordance with section 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation), NTG Nordic Transport Group A/S (“NTG”), CVR no. 12546106, hereby announces receipt of the following notification from persons discharging...
Nasdaq GlobeNewswire
07/06/2023

Reporting of transactions made by persons discharging managerial…

Company announcement no. 28 - 237 June 2023 Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares In accordance with section 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation), NTG Nordic Transport Group A/S (“NTG”), CVR no. 12546106, hereby announces receipt of the following notification from persons discharging...
Nasdaq GlobeNewswire
07/06/2023

Amarna Therapeutics announces appointment of Dr Henk Streefkerk as new CEO

"We are very pleased to introduce Henk Streefkerk as our new CEO. As a Physician Scientist he brings to Amarna a broad and extensive experience in clinical development, health authority negotiations, and other regulatory interactions. Henk will be instrumental in leading Amarna towards the first in human clinical trial," said Thomas Eldered, Chairman of Amarna's supervisory board. " We are very pleased to introduceHenk Streefkerkas our new CEO. As a Physician Scientist he brings…
PR Newswire
07/06/2023
Altri  Comunicati